Review demonstrates diverse therapeutic bioactivities of animal by-product peptides in food systems, indicating defined mixtures offer the most practical route to commercialization.
Animal-processing by-products contain collagen, myofibrillar proteins, blood proteins, whey proteins, and egg proteins that can be converted into peptide-rich food ingredients. Within a single application-oriented framework, this review integrates source heterogeneity, process control, peptide-profile characterization, tiered functional evidence, food-matrix performance, and regulatory substantiation. Evidence is evaluated for antioxidant, ACE-inhibitory, antimicrobial, DPP-IV-inhibitory, anti-inflammatory, mineral-binding, and taste-modulating functions, while distinguishing chemical assays, cell models, animal studies, human interventions, and tests in real-food matrices. Potential applications include functional foods, dietary supplements, natural preservation, flavor systems, texture modification, active packaging, and oral delivery. Translation remains limited by raw-material heterogeneity, batch variability, sensory defects, processing and gastrointestinal instability, uncertain bioavailability, incomplete safety assessment, and poorly defined regulatory claims. Future work should prioritize source traceability, peptide fingerprints, food-matrix validation, human exposure data, and scalable food-grade production. Compositionally defined peptide mixtures with reproducible functionality may be more practical than single highly purified sequences.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: